Odyssey Therapeutics Acquires Rahko

Odyssey Therapeutics, a Boston based company developing next-generation precision medicines for patients with inflammatory diseases and cancer has acquired a majority stake in Rahko. The value of the transaction has not been made public. Odyssey is a new pharmaceutical startup that just received a Series A venture investment of $218 million earlier this month and apparently has put some of the money to immediate use with the Rahko acquisition. Rahko was founded in 2018 by computer science graduates from University College London (UCL) and has developed a software product called Hyrax which can provide faster and cheaper drug discovery. Their solution currently uses classical AI algorithms now, but they are planning to use quantum computing in the future once better performing quantum computing hardware becomes available. A press release from Odyssey Therapeutics announcing the acquisition can be found here.

December 17, 2021